The Clinical Times
The Front Page of Medicine

Infectious Disease · 2025

Gepotidacin (Blujepa), first new oral antibiotic class in decades

Blujepa; EAGLE trials

Chemical structure of gepotidacin, a first-in-class triazaacenaphthylene antibiotic
Ed (Edgar181) / Public domain (Wikimedia Commons)

Antibiotic resistance had been eroding the reliability of standard regimens for uncomplicated urinary tract infection and gonorrhea for years before gepotidacin reached approval. Fluoroquinolone resistance in E. coli, the dominant UTI pathogen, had risen high enough that many guidelines had already downgraded the class from first-line use in uncomplicated cystitis. Neisseria gonorrhoeae presented an even more urgent problem: after fluoroquinolone resistance rendered that class obsolete for gonorrhea around 2007, ceftriaxone became the last reliable option, and strains with reduced ceftriaxone susceptibility had been documented across multiple continents. The pipeline of new gonorrhea therapeutics had been nearly empty for three decades.

Gepotidacin belongs to a new chemical class, the triazaacenaphthylenes, and works by inhibiting bacterial type IIA topoisomerases through a binding site distinct from the one targeted by fluoroquinolones. Because the mechanism operates at a different location on the enzyme, existing fluoroquinolone resistance mutations, including the common gyrA and parC substitutions, do not confer resistance to gepotidacin. That dual topoisomerase inhibition, hitting both DNA gyrase and topoisomerase IV simultaneously at a new site, raises the barrier to de novo resistance development. Michael Dunbar led the clinical development program at GSK.

The EAGLE phase 3 trials for uncomplicated UTI compared gepotidacin against nitrofurantoin and demonstrated non-inferiority. The FDA approved gepotidacin under the brand name Blujepa in 2025 for uncomplicated UTIs caused by susceptible organisms. A separate phase 3 trial for uncomplicated gonorrhea demonstrated high per-protocol cure rates in urogenital infection, supporting a subsequent indication for that pathogen.

The gonorrhea indication represented the first new oral antibiotic class approved for that pathogen in over three decades. Infectious disease specialists had been monitoring the situation closely: as of the early 2020s, dual therapy with ceftriaxone plus azithromycin had already been modified to ceftriaxone alone after azithromycin resistance rose, and the field was functioning with a single-drug option backed by a narrowing spectrum. Gepotidacin's activity against fluoroquinolone-resistant N. gonorrhoeae was the specific property that made it clinically relevant to that gap.

Gepotidacin's spectrum does not cover the full range of organisms encountered in complicated UTI or upper tract infections, so its role in clinical practice is relatively specific: uncomplicated cystitis in settings where resistance limits the standard options, and gonorrhea where fluoroquinolone resistance is documented or suspected. For infectious disease physicians managing urogenital pathogens with resistance, the approval added a mechanistically distinct option that had not existed in oral form for a generation.

Key People

Read the original — FDA

FDA approval, 2025

Related landmarks

← All Landmark Moments